British Columbia Hepatitis Testers Cohort: HCV Reinfection Rate ~ 2/100 PY Following SVR With DAA Treatment Among Persons Who Inject Drugs

November 8-12, 2019; Boston, Massachusetts
HCV reinfection rates in British Columbia were relatively low following SVR with DAA treatment but were higher among persons who inject drugs vs the overall cohort.
Format: Microsoft PowerPoint (.ppt)
File Size: 211 KB
Released: November 20, 2019


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Related Content

CCO slides on the impact of racial disparities in HCV care; key strategies on recognizing and reducing inadequate HCV care in the US and globally

Prof Ashley Brown, BSc, MD, FRCP person default Ahmed M. Elsharkawy, PhD, FRCP(UK) Oluwaseun Falade-Nwulia, MBBS, MPH Joseph K. Lim, MD Released: October 11, 2021

Clinical Care Options (CCO) video featuring Drs. Greg Dore and Stacey Trooskin discussing lessons on HCV care learned during COVID-19 lockdown

Gregory Dore, MBBS, PhD, FRACP, MPH Stacey Trooskin, MD, PhD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: October 1, 2021 Expired: September 30, 2022

Expert commentary on the utility of telemedicine visits in HCV care, from Dr. Stacey Trooskin and Clinical Care Options (CCO)

Stacey Trooskin, MD, PhD, MPH Released: September 29, 2021

Download key slides describing lessons learned in delivery of care from the COVID-19 pandemic worth carrying forward in the management of viral hepatitis.

Gregory Dore, MBBS, PhD, FRACP, MPH Stacey Trooskin, MD, PhD, MPH Released: September 23, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.